Ausgabe 4/2024
Inhalt (15 Artikel)
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants
- Open Access
- Research
Michael J. Hanley, Steven Zhang, Robert Griffin, Sean Xiaochun Zhu, Robert J. Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer
- Research
Tomoya Yokota, Satoshi Hamauchi, Takeshi Kawakami, Kunihiro Fushiki
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis
- Research
Panpan Luo, Yuge Guo, Yang He, Chunjiang Wang
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
- Open Access
- Research
Noboru Yamamoto, Yasutoshi Kuboki, Kenichi Harano, Takafumi Koyama, Shunsuke Kondo, Akiko Hagiwara, Noriko Suzuki, Ei Fujikawa, Kiichiro Toyoizumi, Mayumi Mukai, Toshihiko Doi
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas
- Open Access
- Research
Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H. Sehn, Erwan Beauchamp, Michael Weickert, Luc G. Berthiaume, John R. Mackey
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
- Open Access
- Research
Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, Shunji Watanabe, Masafumi Ikeda, Hidekatsu Kuroda, Tomokazu Kawaoka, Atsushi Hiraoka, Yutaka Yasui, Teiji Kuzuya, Rui Sato, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Masato Nakamura, Soichiro Kiyono, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Yoshihito Ozawa, Kaoru Tsuchiya, Masanori Atsukawa, Hiroshi Aikata, Takeshi Aramaki, Shiro Oka, Naoki Morimoto, Masayuki Kurosaki, Yoshito Itoh, Namiki Izumi, Naoya Kato
Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts
- Research
Hongwei Liu, Qianqian Wang, Wanying Lan, Duanya Liu, Jiangang Huang, Jie Yao
Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics
- Research
Kai Fan, Yueyuan Wang, Jiangyujing Bian, Yewen Sun, Jiaqi Dou, Jie Pan, Yunli Yu
A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor
- Research
Jingqiao Wu, Zhaoyu Lan, Xin Li, Jinling He, Dongchao Zhang, Tianming Jin
Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer
- Research
Yanqi Zhong, Heng Zhang, Peng Wang, Jing Zhao, Yuxi Ge, Zongqiong Sun, Zi Wang, Jie Li, Shudong Hu
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
- Research
Jing Zhang, Wenwei Yang, Junbao Liu, Nan Wang, Zhaoying Ren, Tingting Yang, Gongli Xie, Guifu Wu, Yongkun Sun
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study
- Open Access
- Research
Dongmei Ji, Weina Shen, Ting Li, Huan Wang, Jianling Bai, Junning Cao, Xichun Hu
177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model
- Open Access
- Brief Report
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else
- Correspondence
Nicholas G. Kounis, Virginia Mplani
